735 related articles for article (PubMed ID: 32794076)
1. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.
Dai Y; Wang W; Yu Y; Hu S
Clin Rheumatol; 2021 Apr; 40(4):1211-1220. PubMed ID: 32794076
[TBL] [Abstract][Full Text] [Related]
2. Management issues in rheumatoid arthritis-associated interstitial lung disease.
England BR; Hershberger D
Curr Opin Rheumatol; 2020 May; 32(3):255-263. PubMed ID: 32141954
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
[TBL] [Abstract][Full Text] [Related]
4. Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
Tardella M; Di Carlo M; Carotti M; Giovagnoni A; Salaffi F
Clin Rheumatol; 2021 Dec; 40(12):4861-4867. PubMed ID: 34313866
[TBL] [Abstract][Full Text] [Related]
5. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
[TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
Rojas-Serrano J; Herrera-Bringas D; Pérez-Román DI; Pérez-Dorame R; Mateos-Toledo H; Mejía M
Clin Rheumatol; 2017 Jul; 36(7):1493-1500. PubMed ID: 28585060
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.
Akiyama M; Kaneko Y
Autoimmun Rev; 2022 May; 21(5):103056. PubMed ID: 35121155
[TBL] [Abstract][Full Text] [Related]
8. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
[TBL] [Abstract][Full Text] [Related]
9. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
Mena-Vázquez N; Godoy-Navarrete FJ; Manrique-Arija S; Aguilar-Hurtado MC; Romero-Barco CM; Ureña-Garnica I; Espildora F; Añón-Oñate I; Pérez-Albaladejo L; Gomez-Cano C; Jimenez-Núñez FG; Padin-Martín MI; Fernández-Nebro A
Clin Rheumatol; 2021 Jan; 40(1):133-142. PubMed ID: 32557255
[TBL] [Abstract][Full Text] [Related]
10. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
Roubille C; Haraoui B
Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
Sparks JA; He X; Huang J; Fletcher EA; Zaccardelli A; Friedlander HM; Gill RR; Hatabu H; Nishino M; Murphy DJ; Iannaccone CK; Mahmoud TG; Frits ML; Lu B; Rosas IO; Dellaripa PF; Weinblatt ME; Karlson EW; Shadick NA; Doyle TJ
Arthritis Rheumatol; 2019 Sep; 71(9):1472-1482. PubMed ID: 30951251
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and prognosis of acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.
Xie M; Zhu C; Ye Y
BMC Pulm Med; 2023 Jul; 23(1):255. PubMed ID: 37434169
[TBL] [Abstract][Full Text] [Related]
14. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
Fernández-Díaz C; Loricera J; Castañeda S; López-Mejías R; Ojeda-García C; Olivé A; Rodríguez-Muguruza S; Carreira PE; Pérez-Sandoval T; Retuerto M; Cervantes-Pérez EC; Flores-Robles BJ; Hernández-Cruz B; Urruticoechea A; Maíz-Alonso O; Arboleya L; Bonilla G; Hernández-Rodríguez Í; Palma D; Delgado C; Expósito-Molinero R; Ruibal-Escribano A; Álvarez-Rodríguez B; Blanco-Madrigal J; Bernal JA; Vela-Casasempere P; Rodríguez-Gómez M; Fito C; Ortiz-Sanjuán F; Narváez J; Moreno M; López-Corbeto M; Mena-Vázquez N; Aguilera-Cros C; Romero-Yuste S; Ordóñez S; Villa-Blanco I; Gonzélez-Vela MC; Mora-Cuesta V; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
Semin Arthritis Rheum; 2018 Aug; 48(1):22-27. PubMed ID: 29422324
[TBL] [Abstract][Full Text] [Related]
15. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.
Fernández-Díaz C; Atienza-Mateo B; Castañeda S; Melero-Gonzalez RB; Ortiz-SanJuan F; Loricera J; Casafont-Solé I; Rodríguez-García S; Aguilera-Cros C; Villa-Blanco I; Raya-Alvarez E; Ojeda-García C; Bonilla G; López-Robles A; Arboleya L; Narváez J; Cervantes E; Maiz O; Alvarez-Rivas MN; Cabezas I; Salgado E; Hidalgo-Calleja C; Fernández S; Fernández JC; Ferraz-Amaro I; González-Gay MA; Blanco R;
Rheumatology (Oxford); 2021 Dec; 61(1):299-308. PubMed ID: 33779697
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Vicente-Rabaneda EF; Atienza-Mateo B; Blanco R; Cavagna L; Ancochea J; Castañeda S; González-Gay MÁ
Autoimmun Rev; 2021 Jun; 20(6):102830. PubMed ID: 33887489
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
18. Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept.
Mochizuki T; Ikari K; Yano K; Sato M; Okazaki K
Mod Rheumatol; 2019 May; 29(3):413-417. PubMed ID: 29798700
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Crestani B; Dieudé P
Curr Opin Pulm Med; 2020 Sep; 26(5):477-486. PubMed ID: 32701675
[TBL] [Abstract][Full Text] [Related]
20. Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology.
Wu EK; Ambrosini RD; Kottmann RM; Ritchlin CT; Schwarz EM; Rahimi H
Curr Rheumatol Rev; 2019; 15(4):277-289. PubMed ID: 30652645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
